Robert Goldman

Company: MapLight Therapeutics

Job title: Senior Vice President, Head, Medical Affairs

Seminars:

Panel Discussion: Advances in the Development of Muscarinic Agonists – Learnings from Clinical Trials, Addressing Biology & Subtype Selectivity 10:00 am

 What can we learn from the failure of Emraclidine? What can we decipher from post-mortem analyses? How much of a role did trial oversight and placebo responses influence the results of the EMPOWER trials? Understanding Subtype-Specific Functions. Is M1 and M4 receptor agonism necessary for efficacy?Read more

day: Day One